Analyst: Darzalex sales could reach top end of projections

Janssen’s recently published sales figures for cancer drug Darzalex indicate a promising year-end result is in store, according to a Sydbank analyst.

Photo: PR / Genmab

On Tuesday, Genmab saw a bad stock market start turn around after its partner, US-based pharmaceutical firm Johnson & Johnson, released its first quarter figures for 2022, which revealed a sales advancement for bone marrow cancer drug Darzalex.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs